Vitiligo
☆ AI Dermatology — Free Service
Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
Nos resultados de Stiftung Warentest de Alemaña de 2022, a satisfacción dos consumidores con ModelDerm foi só lixeiramente inferior á das consultas de telemedicina pagas.
O vitíligo dos dedos é máis difícil de tratar que noutras áreas. Ademais de ser cosméticamente antiestético, o vitíligo é normal e non contagioso. En dermatoloxía, o tratamento máis eficaz é a fototerapia ou o tratamento con láser (excimer) 2‑3 veces por semana durante polo menos un ano. Se non pode ir ao hospital a miúdo por razóns económicas ou porque está ocupado, pode probar unha máquina de fototerapia que estea aprobada para uso doméstico.
Vitiligo palpebral
Vitiligo na man
relevance score : -100.0%
ReferencesO vitiligo é un trastorno común da pel que causa manchas brancas na pel debido á perda de melanocitos. Investigacións recentes demostran que se trata dunha enfermidade autoinmune. Aínda que a miúdo se considera un problema cosmético, pode afectar profundamente o benestar mental e a vida diaria. En 2011, os expertos clasificaron un tipo chamado segmental vitiligo como distinto dos demais.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Os pacientes con vitíligo activo teñen varias opcións de terapia, como glucocorticoides sistémicos, fototerapia e inmunosupresores sistémicos. Os pacientes con vitíligo estable poden obter alivio dos corticosteroides tópicos, inhibidores de calcineurina tópicos, fototerapia e procedementos de transplante. Os avances recentes na comprensión dos procesos subxacentes do vitíligo levaron ao desenvolvemento de terapias dirixidas. Actualmente, os inhibidores de JAK son os máis prometedores, pois ofrecen boa tolerabilidade e resultados funcionais, a pesar do risco de activar infeccións latentes e de efectos secundarios sistémicos comúns con outros axentes inmunosupresores. A investigación en curso ten como obxectivo identificar as citocinas clave implicadas no desenvolvemento do vitíligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). O bloqueo destas citocinas mostrouse prometedor en modelos animais e nalgúns pacientes. Ademais, están en curso investigacións sobre miRNA-based therapeutics e adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Non hai cura coñecida para o vitíligo. Para as persoas con pel clara recoméndanse o uso de protector solar e maquillaxe. Outras opcións de tratamento poden incluír cremas esteroides ou fototerapia.
○ Tratamento
#Phototherapy
#Excimer laser
#Tacrolimus ointment